PROCEPT BioRobotics to Present at Upcoming 2024 Wells Fargo Healthcare Conference on September 4, 2024

Rhea-AI Summary

PROCEPT BioRobotics (Nasdaq: PRCT), a surgical robotics company specializing in urology solutions, has announced its participation in the 2024 Wells Fargo Healthcare Conference in Boston. The company's management team is scheduled to present on Wednesday, September 4, 2024, at 1:30 p.m. Eastern Time.

Investors and interested parties can access a live webcast of the presentation through the company's website at https://ir.procept-biorobotics.com. The webcast will also be archived for at least 90 days after the event, allowing for later viewing. This presentation offers an opportunity for PROCEPT BioRobotics to showcase its innovative urological solutions and connect with healthcare industry professionals and investors.

SAN JOSE, Calif., Aug. 28, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics^® (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that members of management will present at the upcoming 2024 Wells Fargo Healthcare Conference in Boston, Massachusetts. Management is scheduled to present on Wednesday, September 4 at 1:30 p.m. Eastern Time.

A live webcast of each event, as well as an archived recording, will be available on the “Investors” section of the company’s website at: https://ir.procept-biorobotics.com. The webcasts will be archived and available for replay for at least 90 days after the event.

About PROCEPT BioRobotics Corporation

PROCEPT BioRobotics is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The HYDROS^TM Robotic System is the only AI-Powered, robotic technology that delivers Aquablation therapy. PROCEPT BioRobotics designed Aquablation therapy to deliver effective, safe, and durable outcomes for males suffering from lower urinary tract symptoms or LUTS, due to BPH that are independent of prostate size and shape or surgeon experience. BPH is the most common prostate disease and impacts approximately 40 million men in the United States. The Company has developed a significant and growing body of clinical evidence with over 150 peer-reviewed publications, supporting the benefits and clinical advantages of Aquablation therapy.

Investor Contact:
Matt Bacso
VP, Investor Relations and Business Operations
m.bacso@procept-biorobotics.com

FAQ

When is PROCEPT BioRobotics (PRCT) presenting at the 2024 Wells Fargo Healthcare Conference?

PROCEPT BioRobotics (PRCT) is scheduled to present at the 2024 Wells Fargo Healthcare Conference on Wednesday, September 4, 2024, at 1:30 p.m. Eastern Time.

Where can I watch the PROCEPT BioRobotics (PRCT) presentation at the Wells Fargo Healthcare Conference?

You can watch a live webcast of the PROCEPT BioRobotics (PRCT) presentation on the 'Investors' section of the company's website at https://ir.procept-biorobotics.com.

How long will the PROCEPT BioRobotics (PRCT) webcast be available after the Wells Fargo Healthcare Conference?

The webcast of PROCEPT BioRobotics' (PRCT) presentation will be archived and available for replay for at least 90 days after the event.

What is the focus of PROCEPT BioRobotics (PRCT) as a company?

PROCEPT BioRobotics (PRCT) is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology.